<DOC>
	<DOCNO>NCT01861509</DOCNO>
	<brief_summary>This study open label , non-randomized phase I single-armed study woman metastatic breast cancer ( MBC ) previously undergone available standard chemotherapy regimen . The purpose study estimate pharmacokinetics ( PK ) single dose multiple dose BP-C1 , investigate interleukin level BP-C1 treatment ass treatment response accord RECIST criterion .</brief_summary>
	<brief_title>BP-C1 Metastatic Breast Cancer Patients</brief_title>
	<detailed_description>BP-C1 , solution injection 0.05 % , currently develop treatment patient metastatic breast cancer palliative intent . Active substance product , novel platinum-containing anticancer agent develop intramuscular administration , cis-coordinated complex platinum ( II ) polymer benzene polycarboxylic acid derive lignin ( CDBPA ) . The product complex cis-diammineplatinum ( II ) derive core amphiphilic polymer , contain composition benzene polycarboxylic acid . The amphiphilic characteristic polymer result product clear significantly alter improved property compare platinum analogue , e.g . cisplatin , carboplatin oxaliplatin . BP-C1 preserve antitumour activity predecessor ( e.g . cisplatin carboplatin ) , additionally offer follow advantage ensure favourable outcome treatment metastatic breast cancer patient : - injectable solution ( intramuscular ) cause injection site reaction ; - administer home nurse patient ; - improve pharmacokinetic profile ; - demonstrate efficacy comparable cisplatin much high carboplatin ( in-vitro ; in-vivo data ) ; - exert additional immunomodulatory activity . In study six female patient MBC previously undergone available standard chemotherapy regimen enrol . Each include patient participate screening period ( maximum duration 21 day ) follow 32-day treatment period 28-day follow-up period . The patient treat BP-C1 ( daily intramuscular injection ) 32 consecutive day . The study undertaken evaluate pharmacokinetics , pharmacodynamics treatment effect BP-C1 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Female patient metastatic breast cancer ( MBC , stage IV ) 2 . 18 80 year age 3 . Measurable lesion / lymph node 4 . Have previously undergo available standard chemotherapy 5 . Expected survival time exceed 3 month 1 . Abnormal liver function classify total bilirubin &gt; 34 μmol/L ALAT &gt; 3 time upper limit normal range ( ULN ) . In case metastasis liver , ALAT limit exclusion set 5xULN . Retest result blood sample take 2 day Day1 must keep meeting eligibility criterion . 2 . Abnormal kidney function define serum creatinine &gt; 120 μmol/L . Retest result blood sample take 2 day Day1 must keep meeting eligibility criterion . 3 . Abnormal coagulation capacity define relative arbitrary concentration coagulation factor 2,7,10 INR &gt; 1.3 . Retest result blood sample take 2 day Day1 must keep meeting eligibility criterion . 4 . Brain metastasis symptomatic patient require ≥4 mg dexamethasone/day . However , patient treat brain metastasis surgery radiation stable symptomfree ( &lt; 4 mg dexamethasone/day ) minimum period 4 week prior study treatment eligible . 5 . Synchronous cancer except nonmelanoma skin cancer early stage cervical cancer . 6 . Abnormal haematology status define Hb &lt; 9.0 g/dL , platelet count &lt; 75,000/mm^3 leukocyte &lt; 3x10^9/L . Retest result blood sample take 2 day Day1 must keep meeting eligibility criterion . 7 . Clinically significant abnormal ECG . 8 . Karnofsky Performance Status Score &lt; 50 % . 9 . Pregnant breast feed woman . 10 . Women fertile age want test possible pregnancy . 11 . Fertile female want use safe protection pregnancy , start one month start trial treatment last least six week . 12 . Uncontrolled bacterial , viral , fungal parasite infection . 13 . Under systemic treatment corticosteroid immunosuppressive drug last 21 day start trial treatment . Systemic treatment &lt; 4 mg dexamethasone/day allow 14 . Participating another clinical trial pharmaceutical last six week start trial treatment . 15 . Not able understand write oral information . 16 . Do want able give write consent participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BP-C1</keyword>
	<keyword>CDBPA</keyword>
	<keyword>Metronomic chemotherapy</keyword>
	<keyword>Platinum analogue</keyword>
	<keyword>Cis-coordinated complex platinum ( II ) polymer benzene polycarboxylic acid derive lignin</keyword>
	<keyword>Benzene polycarboxylic acid complex cis-diammineplatinum ( II )</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>